FMT holds potential for treating various diseases beyond C. difficile infection, but its regulation by the FDA is crucial due to concerns about long-term effects and unintentional disease transfer.
Keep Reading
Add A Comment
Trending
- The colonoscopy reimbursement math is not adding up (Becker’s Healthcare)
- Gastroenterologists flag clinical remission and its durability as unmet needs in IBD care: survey (Fierce Healthcare)
- Microbiome Testing Needs Its Standards Moment (Op-Med)
- Combined GI Endoscopy Has a Quality Assurance Gap. At Current Volume, That Gap Has Institutional Consequences. (HIT Consultant)
- Computer-aided polyp detection multicenter international randomized controlled study with a focus on community clinics: Gastroenterology Artificial INtelligence system for detecting colorectal polyps (ScienceDirect)
- Researchers Analyzing Colon Cancer Screenings Find Hope for Higher Retest Rates (Rutgers)
- Exclusive: Co-Founded By Former Whoop CTO, Throne Science Raises $10M To Track Gut Health From The Toilet (Crunchbase)
- GI Societies Oppose Proposed Federal Rule That Would Reshape Biomedical Research (American College of Gastroenterology)
